Jandhyala R - Search Results

1

Factors Influencing the Generation of Evidence from Simple Data Held in International Rare Disease Patient Registries.

Jandhyala R, Christopher S. Jandhyala R, et al. Pharmaceut Med. 2020 Feb;34(1):31-38. doi: 10.1007/s40290-019-00316-w. Pharmaceut Med. 2020. PMID: 32048210

2

A simple core dataset for triglyceride-induced acute pancreatitis.

Freedman S, de-Madaria E, Singh VK, Bruckert E, Löhr M, Sutton R, Rebours V, Jones R, Jandhyala R. Freedman S, et al. Among authors: jandhyala r. Curr Med Res Opin. 2023 Jan;39(1):37-46. doi: 10.1080/03007995.2022.2144054. Epub 2022 Nov 23. Curr Med Res Opin. 2023. PMID: 36384356

3

Comment on: "Patient Registries: An Underused Resource for Medicines Evaluation: Operational Proposals for Increasing the Use of Patient Registries in Regulatory Assessments".

Jandhyala R. Jandhyala R. Drug Saf. 2019 Dec;42(12):1515-1516. doi: 10.1007/s40264-019-00862-x. Drug Saf. 2019. PMID: 31552605 No abstract available.

4

Influence of Pharmaceutical Company Engagement Activities on the Decision to Prescribe: A Pilot Survey of UK Rare Disease Medicine Prescribers.

Jandhyala R. Jandhyala R. Pharmaceut Med. 2020 Apr;34(2):127-134. doi: 10.1007/s40290-019-00323-x. Pharmaceut Med. 2020. PMID: 32048216

5

The multiple stakeholder approach to real-world evidence (RWE) generation: observing multidisciplinary expert consensus on quality indicators of rare disease patient registries (RDRs).

Jandhyala R. Jandhyala R. Curr Med Res Opin. 2021 Jul;37(7):1249-1257. doi: 10.1080/03007995.2021.1927689. Epub 2021 May 21. Curr Med Res Opin. 2021. PMID: 33989087

6

Estimation of Reduction in Influenza Vaccine Effectiveness Due to Egg-Adaptation Changes-Systematic Literature Review and Expert Consensus.

Ortiz de Lejarazu-Leonardo R, Montomoli E, Wojcik R, Christopher S, Mosnier A, Pariani E, Trilla Garcia A, Fickenscher H, Gärtner BC, Jandhyala R, Zambon M, Moore C. Ortiz de Lejarazu-Leonardo R, et al. Among authors: jandhyala r. Vaccines (Basel). 2021 Oct 29;9(11):1255. doi: 10.3390/vaccines9111255. Vaccines (Basel). 2021. PMID: 34835186 Free PMC article. Review.

7

Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument.

Jandhyala R. Jandhyala R. Pharmaceut Med. 2022 Feb;36(1):47-57. doi: 10.1007/s40290-021-00413-9. Epub 2022 Jan 7. Pharmaceut Med. 2022. PMID: 34994965 Free PMC article.

8

The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines Agency.

Jandhyala R. Jandhyala R. J Pharm Policy Pract. 2022 May 4;15(1):36. doi: 10.1186/s40545-022-00433-z. J Pharm Policy Pract. 2022. PMID: 35509059 Free PMC article.

9

Concordance between the schedule for the evaluation of individual quality of life-direct weighting (SEIQoL-DW) and the EuroQoL-5D (EQ-5D) measures of quality of life outcomes in adults with X-linked hypophosphatemia.

Jandhyala R. Jandhyala R. Orphanet J Rare Dis. 2022 Feb 23;17(1):81. doi: 10.1186/s13023-022-02250-8. Orphanet J Rare Dis. 2022. PMID: 35197083 Free PMC article.

10

Neutral theory: applicability and neutrality of clinical study endpoints where a disease-specific instrument is available.

Jandhyala R. Jandhyala R. BMC Med Res Methodol. 2023 May 20;23(1):121. doi: 10.1186/s12874-023-01947-z. BMC Med Res Methodol. 2023. PMID: 37210484 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

45 results

Search Page